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Abstract: A novel bromide salt of the antidepressant bupropion (bupropion HBr) has recently 
been developed and approved for use in the United States. Given previous use of bromides to 
treat seizures, and that the existing chloride salt of bupropion (HCl) can cause seizures, it is 
important to determine if the HBr salt may be less likely to cause seizures than the HCl salt. In the 
present animal studies this was evaluated by means of quantiﬁ  ed electroencephalogram (EEG), 
observation, and the rotarod test in mice and rats. Both bupropion salts were tested at increasing 
equimolar doses administered intraperitoneally. The results in mice showed that bupropion HCl 
125 mg/kg induced a signiﬁ  cantly higher ten-fold increase in the mean number of cortical EEG 
seizures compared to bupropion HBr (7.50 ± 2.56 vs 0.75 ± 0.96; p = 0.045), but neither drug 
caused any brain injuries. In rats bupropion HBr 100 mg/kg induced single EEG seizure activity 
in the cortical and hippocampal (depth) electrodes and in signiﬁ  cantly (p  0.05) fewer rats 
(44%) compared to bupropion HCl, which induced 1 to 4 convulsions per rat in all rats (100%) 
dosed. The total duration of cortical seizures in bupropion HCl-treated rats was signiﬁ  cantly 
longer than the corresponding values obtained in bupropion HBr-treated rats (424.6 seconds 
vs 124.5 seconds respectively, p  0.05). Bupropion HCl consistently induced more severe 
convulsions at each dose level compared to bupropion HBr. Both treatments demonstrated a 
similar dose-dependent impairment of rotarod performance in mice. In conclusion, these ﬁ  nd-
ings suggest that bupropion HBr may have a signiﬁ  cantly lower potential to induce seizures 
in mice and rats, particularly at higher doses, compared to bupropion HCl. Determination of 
this potential clinical advantage will require human studies. If conﬁ  rmed by such studies, it is 
likely that this potential beneﬁ  cial clinical beneﬁ  t would be due to the presence of the bromide 
salt given the long history of the use of bromide to treat seizure disorders.
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Introduction
Bupropion hydrochloride (HCl), a widely used antidepressant, is associated with a 
dose-dependent risk of seizures when given at therapeutic doses or following over-
dose in humans,1–6 and in animals.7,8 The precise mechanism of bupropion-induced 
seizures remains unknown. Recently, Biovail (Biovail Laboratories International SRL, 
St. Michael, Barbados) has developed a new extended-release tablet formulation of 
bupropion hydrobromide (HBr) for once-daily administration. The administration of 
bupropion HBr to steady-state levels was safe and well tolerated for up to ﬁ  ve weeks 
in healthy nonsmoking adult volunteers.9 The bromide salt was chosen for stability 
reasons. However, once developed there arose the possibility that this formulation 
had a reduced seizure risk compared to bupropion HCl. This is because high-dose 
bromide is associated with treatment of seizures. Bromides were ﬁ  rst introduced in the 
treatment of seizures in 1857 by Sir Charles Locock10,11 and gained wide usage until Neuropsychiatric Disease and Treatment 2009:5 190
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the introduction of phenobarbital in 1912. When phenytoin 
was introduced in 1937, it heralded the demise of bromides 
as antiepileptic drugs in the modern age of antiepileptics.12 
Although the mechanism of action of bromide as an antisei-
zure agent is not known, developing a hydrobromide salt of 
bupropion may therefore potentially reduce the seizure risk 
associated with the use of bupropion.
The objectives of these studies were to: (i) assess the elec-
troencephalographic and behavioral convulsant, and central 
nervous system effects of bupropion HBr in comparison to 
the effects of equimolar doses of bupropion HCl in conscious 
mice and rats, and (ii) show a difference, if any, in the sensi-
tivity of the rodents to the two salts of bupropion.
Materials and methods
Mice electroencephalogram study
The objectives of this study were to: (a) determine the com-
parative cortical electroencephalogram (EEG) proconvulsant 
effects of equimolar doses of bupropion HCl and bupropion 
HBr in mice, and (b) determine if the bupropion-induced 
seizures were associated with any histopathological brain 
injury, and if so, determine any differences between the two 
salts in the magnitude of the injury.
The study was conducted at the In vivo Neuroscience 
Laboratory, Department of Physiology and Medical Physics, 
Royal College of Surgeons in Ireland, Dublin, Ireland. All 
experimental and operational procedures were performed in 
accordance with the current standard operating procedures 
of the Biomedical Research Facility at the Royal College of 
Surgeons in Ireland and the research study was undertaken 
under the remit of current Research Ethics Committee approval 
for the study of seizure effects in mouse models (REC 098).
Animals
Thirty (30) female CD-1 mice (Charles River laboratories, 
Margate, Kent, UK) weighing 25–29 g were housed in groups 
of ﬁ  ve to six per cage in standard polypropylene cages for 
mice with stainless steel lids in the Biomedical Research 
Facility. They were acclimatized for a minimum period of 
four days with standard laboratory rodent processed sawdust 
used as bedding material in the cages in an environmentally 
controlled animal room (temperature 22 ± 3 °C; relative 
humidity 50% ± 20%) with a 12-hour light/dark cycle. Each 
cage was identiﬁ  ed using cage cards with information on 
the researcher/principal investigator, study number, cage 
number, animal number, number of animals, species, strain, 
sex, signature of technician and start date. After allocation 
to groups, each animal was uniquely identiﬁ  ed by markings 
on the dorsal surface of the tail. The cages were changed 
weekly or as necessary. Throughout the study, all animals 
had free access ad libitum to feed and mains water via plastic 
water bottles. Prior to the initiation of treatment, animals 
were randomly assigned to doses as follows: Group 1: 
150 mg/kg by intraperitoneal (IP) injection–bupropion HCl 
(n = 4 mice), and bupropion HBr (n = 4 mice); Group 2: 
135 mg/kg IP–bupropion HCl (n = 2 mice), and bupropion 
HBr (n = 2 mice); Group 3: 125 mg/kg IP–bupropion HCl 
(n = 4 mice), and bupropion HBr (n = 4 mice); Group 4: 
115 mg/kg IP–bupropion HCl (n = 2 mice), and bupropion 
HBr (n = 2 mice); and Group 5: 100 mg/kg IP–bupropion 
HCl (n = 2 mice), and bupropion HBr (n = 2 mice). A clinical 
examination was performed on each animal by a trained 
technician at the start of acclimatization and on study day –1. 
Animals in poor health or those considered unsuitable for 
use in the study were not assigned to treatment groups and 
unassigned animals were released from the study.
Drugs
Bupropion HCl was obtained from Biovail Technologies 
(Ireland) Ltd. (Manufacturer: Erregierre Sp.A., San Paolo 
d’Argon [BG], Italy), in white powder form, with lot number 
GP0409070, expiry date of September 2006, and was stored 
in a cool (15–25 °C), dry place protected from light. Bupro-
pion HBr was obtained from Biovail Technologies (Ireland) 
Ltd. (Manufacturer: Chemi SPA, Patrica [FR], Italy), in 
white powder form, with lot number E00287, expiry date of 
November 2006, and was stored in a cool (15–25 °C), dry place 
protected from light. The diluent was 0.9% sodium chloride 
solution (IV infusion BP) obtained from Baxter Healthcare 
Ltd. (Norfolk, England, UK), with lot number 05L22BS, 
expiry date of November 2007, and was stored at 25 °C.
The dose formulations of both bupropion HCl and 
bupropion HBr were prepared on each day of administration. 
The appropriate amount of bupropion HCl or bupropion HBr 
was weighed into a suitable container and added to 0.9% 
sodium chloride solution to achieve the desired concentration 
of each compound. Bupropion HBr was adjusted to be 
equimolar to bupropion HCl. The mixture was shaken for 
5 min followed by sonication for 5 min, if required, until 
dissolved. On each day of treatment, bupropion HCl was 
administered by IP injection in a dose volume of 10 ml/kg and 
dose concentration of either 10, 11.5, 12.5, 13.5, or 15 mg/ml 
for the 100, 115, 125, 135, and 150 mg/kg doses, respectively. 
Similarly, on each day of treatment, bupropion HBr was 
administered by IP injection in a dose volume of 10 ml/kg 
and dose concentration of either 11.6, 13.34, 14.5, 15.7, or Neuropsychiatric Disease and Treatment 2009:5 191
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17.4 mg/ml for the 100, 115, 125, 135, and 150 mg/kg doses, 
respectively. The actual dose administered was based on the 
most recent body weight of each animal.
Study procedure
All animals were weighed and their body weights were 
recorded on study day −1 and study day 0. General health 
observations were performed on all animals twice daily, at 
least ﬁ  ve hours apart, except at weekends when they were 
performed once daily from the start of acclimatization up to 
and including the ﬁ  nal day of the study.
Electrode placement
After the acclimation period, habituated mice were 
anesthetized with isoﬂ  urane, then placed in a stereotaxic 
frame and maintained normothermic (36–37 °C) by means of 
a feedback-controlled mouse-designed homeothermic blanket 
(Harvard Apparatus, Holliston, MA, USA). Under isoﬂ  urane 
anesthesia, a midline skin incision was made over the skull 
and the skull was exposed. Three partial craniectomies 
were performed, one overlying each temporal lobe and a 
third overlying the frontal cortex. Mouse-sized cranial EEG 
E363/20 electrode with mounting screw and socket (Plastics 
One Inc., Roanoke, VA, USA) were afﬁ  xed at each point. 
The electrode assembly was ﬁ  xed to the skull with dental 
cement, anesthesia was then discontinued and the animal 
was placed in the recording chamber for 30–60 min after 
recovery. The electrodes were connected to a multichannel 
363 Connector Cable System (Plastics One Inc.) with SL6C 
6 channel swivel commutator (Plastics One Inc.). Baseline 
EEG recordings were then commenced using a Grass model 
Comet Portable 40-channel EEG Recording and Review 
System with twin digital EEG in tandem with continuous 
digital video (Astro-Med Inc., West Warwick, RI, USA).
Experimental protocol
After baseline video-EEG recordings for 10 min, mice were 
injected with single doses of bupropion HCl or bupropion 
HBr 100, 115, 125, 135, or 150 mg/kg IP using a 1 ml dispos-
able syringe and 26 gauge needle. Mice were run in parallel 
so that a HCl mouse was injected within minutes of an HBr 
mouse and recordings were made simultaneously. Video-
EEG was recorded for a period of one hour. Thereafter, mice 
were returned to cages and then euthanized at 24 hours and 
the brains harvested for histopathology.
EEG analysis
All EEG were scored visually. The number of occurrences 
and the duration of four patterns of EEG were calculated 
for each mouse over the one hour recording period, using 
the following EEG classiﬁ  cation13 described previously: 
Type 1 – low frequency and amplitude resting/baseline 
EEG; Type II – high frequency, low amplitude ictal fast 
EEG; Type III – low frequency, high amplitude EEG; and 
Type IV – high frequency, high amplitude EEG. EEG seizure 
activity was deﬁ  ned as Type IV polyspike high frequency 
(1 Hz) EEG activity that were 2X the amplitude at base-
line (high amplitude).
Behavioral scoring for the occurrence, number and dura-
tion of seizures was periodically undertaken.
Histopathology study
To investigate whether the recorded EEG seizure activity 
induced by bupropion HCl and bupropion HBr caused any 
brain injury, the tissue sections of harvested mice brains were 
stained with two different markers of neuronal loss/damage: 
terminal deoxynucleotidyl dUTP nick end labeling (TUNEL) 
which identiﬁ  es apoptotic and necrotic neurons in situ,14,15 
and Fluoro-Jade B staining which shows degenerating 
neuronal cells.16–18 In addition, NeuN, a speciﬁ  c marker for 
neurons,19 was used to immunostain viable neurons.
Immunohistochemistry and DNA fragmentation analysis
Since a distinction in EEG seizure activity was only seen 
at the 125 mg/kg dose, the brains from mice treated with 
this dose of each salt of bupropion were extracted whole 
24 hours following administration of the study drug and was 
ﬂ  ash frozen at −20 °C to −30 °C. The brains were stored 
temporarily at −80 °C. Brains from bupropion HCl-treated 
mice (n = 3: Bup9, Bup11 and Bup13) and bupropion 
HBr-treated mice (n = 3: Bup10, Bup12, and Bup14) were 
sectioned at a thickness of 12 μm on a Leica model cryostat 
(Leica Microsystems GmbH, Wetzlar, Germany), each at 
the level of the substantia nigra (bregma), dorsal hippo-
campus and caudate-putamen (striatum). The sections were 
incubated overnight at room temperature in a 1:500 dilution 
of mouse anti-neuronal nuclear protein (NeuN; Chemicon 
International, Inc., Temecula, CA, USA) to label neurons. 
On the second day, sections were stained for cell death using 
terminal deoxynucleotidyl dUTP nick end-labeling (TUNEL; 
Roche Molecular Biochemicals, Indianapolis, IN, USA), 
a marker of double-stranded DNA breaks and apoptosis. 
Sections were then mounted in medium containing 4’, 
6-diamidino-2-phenylindole ([DAPI]; Vector Laboratories, 
Inc., Burlingame, CA, USA) to visualize nuclei. TUNEL were 
examined using a Nikon 2000s epiﬂ  uorescence microscope 
with a 40X oil immersion lens under excitation/emission Neuropsychiatric Disease and Treatment 2009:5 192
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wavelengths of 330–380/420 nm (blue), 472/520 nm (green) 
and 540–580/600–660 nm (red). A total of ten X40 ﬁ  elds 
were selected across each brain area, ﬁ  ve from each side of 
the brain, and a mean count obtained. A cumulative total 
count for each side was taken and then the mean count of 
the two sides was determined. A positive control material 
for permanent seizure damage within the hippocampus 
was provided by injecting kainic acid into the amygdala of 
C57Bl/6 mice, which induces status epilepticus and a lesion 
to hippocampal CA3 neurons. Brieﬂ  y, mice received intra-
amygdala injection of 0.3 μKA (Sigma-Aldrich, St. Louis, 
MO, USA) and sections cut as described above at 24 hours 
as previously described.20,21
Sections of the brains of mice with bupropion HCl- and 
bupropion HBr-induced seizures were also stained with 
Fluoro-Jade B by using the method described by Schmued and 
Hopkins.17,18 The sections were then analyzed as described 
for the TUNEL-stained sections above.
Rat electroencephalogram study
The EEG study in mice, utilizing only cortical electrodes, 
did not detect any seizure activity at the 100, 115, 135, and 
150 mg/kg doses of either salt despite the profound behav-
ioral convulsions observed at the 150 mg/kg dose. Therefore, 
EEG studies in rats were conducted with both cortical and 
stereotaxically implanted hippocampal (depth) electrodes 
to evaluate the effects of IP bupropion HBr compared to 
equimolar doses of bupropion HCl on EEG activity.
The EEG studies in rats were conducted at Porsolt and 
Partners Pharmacology Research Laboratory, Le Genest-
Saint-Isle, France. All experiments were performed in 
accordance with French legislation concerning the protection 
of laboratory animals and in accordance with a currently 
valid license for experiments on vertebrate animals, issued 
by the French Ministry for Agriculture and Fisheries to the 
study director.
Animals
Male Rj: Wistar (Han) rats (Elevage Janvier, Le Genest-Saint-
Isle, France), weighing 280–324 g at the time of electrode 
implantation were housed in groups of ﬁ  ve animals maximum, 
in macrolon cages (44 × 28 × 19 cm) containing wood 
litter (Litalabo – SPPS, Argenteuil, France). The animals 
were housed in an environmentally controlled vivarium 
with ambient temperature of   21 ± 3 °C, relative humidity 
of 30%–80%, and a 12-hour light (7:00 to 19:00) and dark 
cycle. The animals had free access ad libitum to food (Code 
113 – SAFE, Augy, France) and tap water. After electrode 
implantation, the animals were kept individually in macrolon 
cages (30 × 18 × 19 cm) in a separate room for implanted ani-
mals under the same environmental conditions as before and 
had free access to food and tap water except during the test 
sessions. Animals were identiﬁ  ed by marking the connector 
ﬁ  xed on the animal’s head with an indelible pen. Ten animals 
were randomly assigned to each treatment. Animals assigned 
to bupropion HCl received 10, 30, 60, and 100 mg/kg by IP 
injection while animals assigned to bupropion HBr received 
equimolar doses to the bupropion HCl doses, also intraperi-
toneally. Rats were sacriﬁ  ced at the end of the experiments 
humanely by anesthetic overdose.
Dosage selection in this study was based on the results of 
a preliminary dose-ﬁ  nding study that evaluated the effects of 
equimolar doses of bupropion HCl and bupropion HBr in the 
range 30–150 mg/kg IP on the EEG trace in conscious male 
Wistar rats. The results of that study revealed that both salts of 
bupropion induced behavioral convulsions and simultaneous 
EEG seizure activity at doses greater than 70 mg/kg.
Drugs
Bupropion HCl and bupropion HBr were obtained from 
Biovail Technologies (Ireland) Ltd, each in white powder 
form with batch numbers GP0409070 and RM0662, 
respectively. Vehicle was physiological saline (Laboratoire 
Aguettant, Lyon, France) and the substances were dissolved 
in physiological saline and prepared freshly on each day of 
experimentation. All substances were stored in a dry, dark, 
controlled access area and maintained at a controlled ambient 
temperature of 20 ± 3 °C. The vehicle solutions were stored 
at 4 °C. The substances were administered by IP injection 
in a dose volume of 5 ml/kg body weight. The doses of 
bupropion HCl are expressed in mg/kg of salt and the doses 
of bupropion HBr are expressed in mg/kg bupropion HCl 
molar equivalent (correction factor = 1.16).
Study procedure
EEG monitoring in the rat
The effects of the HCl and HBr salts of bupropion on the 
electrical activity in the cortex and hippocampus after IP 
administration were evaluated by EEG trace monitoring 
in the conscious rat according to the method described by 
Dürmüller and colleagues.22
EEG electrode implantation
Electrode implantation surgery was carried out under aseptic 
conditions. Rats were anesthetized with sodium pentobarbital 
60 mg/kg IP, plus supplementary doses of 5–10 mg/kg to Neuropsychiatric Disease and Treatment 2009:5 193
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maintain anesthesia. The rats were then implanted with two 
surface EEG electrodes, consisting of miniature titanium 
screws placed bilaterally over the frontal-parietal cortex, and 
two depth electrodes, consisting of twisted platinum–iridium 
wires placed stereotaxically into the hippocampus CA3 area 
(Paxinos and Watson coordinates interaural: AP +5.0 mm, 
L ± 2.5 mm, V +7.0 mm).23 An additional screw placed over 
the right occipital cortex served as a ground electrode. The 
electrodes were connected to small plugs and the whole 
assembly was secured to the skull with dental acrylate. 
Following surgery, implanted animals were kept in individual 
macrolon cages (30 × 18 × 19 cm) and were allowed at least 
10 days to recover. A total of 27 rats were implanted with 
EEG electrodes.
EEG recording and testing procedure
The animals were placed in rectangular Plexiglas cubicles 
(30 × 10 × 25 cm) mounted on treadmills for the EEG recording. 
Five recording units were run in parallel. A turning commutator 
was attached above the centre of each cubicle, about 30 cm 
above walking level. On one side, it was connected via an 
electrically shielded multicore cable to the animal and on 
the other side to the signal conditioning system (Coulbourn 
Model V75–01; Coulbourn Instruments, Allentown, PA, 
USA). The system ﬁ  lters were set for all channels to 1 Hz and 
150 Hz for the high pass and low pass ﬁ  lters, respectively. 
The ampliﬁ  cation levels were kept between 1,000 and 10,000. 
The EEG signals were acquired and processed on a personal 
computer (PC) installed with a 16 channel analog-to-digital 
data acquisition card that was integrated into a local network 
(Ethernet) which also included a PC for the data analysis, and 
a compact disk (CD) writer for data storage.
Before beginning the testing procedure, the rats were 
habituated in an one-hour training session connected to the 
recording cable and treadmill which activates the animals 
to walk and ensure a heightened level of vigilance.22 A few 
minutes before launching the ﬁ  rst recording, the animals were 
transferred from the holding to the testing room, connected 
to the recording cable, and placed into the recording cubicle. 
The EEG signals were brieﬂ  y inspected for their quality and 
the ampliﬁ  cation levels were adjusted as necessary. The 
animals were then given a one-hour recording session with-
out any treatment (baseline control) and with the treadmill 
intermittently turned on (walking speed: 1.8 m/min) and off 
at intervals of 10 minutes. Immediately after the end of the 
baseline control recording, animals were administered IP 
bupropion HCl or bupropion HBr and recorded for another 
two-hour session. Twenty-three hours after the injection, the 
animals were given an one-hour recording session under the 
same experimental conditions as the day before. Then the 
same recording procedure as on the previous day was repeated 
until all the doses were tested. The same animal was always 
run on the same treadmill, connected to the same unit of the 
signal conditioning system, and the treadmills were always 
operated with the same recording cables. The EEG signal 
acquisition and the visual off-line analysis were performed 
using the IOX2 and ECG_auto softwares (both from EMKA 
Technologies, Paris, France), respectively.
Behavioral observations
Animals were observed for one hour before IP injection of 
treatment (baseline) and for two hours post-treatment for any 
abnormal behaviors, the occurrence and types of seizures and 
the number of animals that had seizures. Behavioral observa-
tions were recorded as the presence or absence of hypersen-
sitivity/stereotypical behaviors, head twitches, rearing, facial 
clonus, forelimb clonus, and wholebody clonus. Post hoc, 
seizure severity was classiﬁ  ed according to the method of 
Racine23 as follows: Class I – Facial clonus; Class II – Head 
nodding; Class III – Forelimb clonus; Class IV – Rearing; 
Class V – Rearing and falling accompanied by wholebody 
clonic seizures.
Assessment of relative behavioral 
proconvulsant activity in mice
The objective of this study was to compare the behavioral 
proconvulsant properties of bupropion HCl and bupropion 
HBr in mice. The study was conducted at Charles River 
Laboratories BioLabs Europe, Ballina, Ireland. The study 
plan was approved by the Ethics Committee of Charles River 
Laboratories BioLabs Europe.
Animals
Sixty (n = 60) healthy female CD-1 mice (Charles River 
Laboratories, Kent, UK) weighing 17.7 to 21.9 g on study 
day 0 were housed in groups of 20 during acclimatization 
and in groups of 5 per cage during the test period. The 
animals were housed in polypropylene cages measuring 
approximately 55 × 34 × 20 cm with stainless steel lids 
and autoclaved dust-free processed sawdust as bedding in 
an environmentally controlled animal room (temperature 
20–23 °C; relative humidity 48%–69%) with artiﬁ  cial lighting 
and a 12-hour light/dark cycle throughout the duration of the 
study. All animals were acclimatized to their cages and to 
the light/dark cycle for at least seven days before the start of 
the study. In addition, all animals were fed Harlan Teklad Neuropsychiatric Disease and Treatment 2009:5 194
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rat and mouse nonirradiated diet (Harlan Teklad, Blackthorn, 
UK) and provided water ad libitum via plastic water bottles 
throughout the study. Animals were randomly assigned to 
six treatment groups of 10 mice per group on study day –1, 
to receive study treatment as follows: three bupropion HCl 
single-dose groups of 100, 125, and 150 mg/kg, and three 
bupropion HBr single-dose groups of the molar equivalent 
doses (to bupropion HCl doses) of 100, 125, and 150 mg/kg. 
The equimolar doses of bupropion HCl and bupropion HBr 
100–150 mg/kg selected for this study were based on the 
results of a dosage range-ﬁ  nding study conducted previously 
in the same strain of mice at the same facility.24
Drugs
Both bupropion HCl and bupropion HBr were obtained from 
Biovail Technologies (Ireland) Ltd., Dublin, Ireland, each in 
white powder form (batch numbers and source: GP0409070, 
and Erregierre Sp.A., San Paolo d’Argon (BG), Italy; and 
E00287, and Chemi SPA, Patrica (FR), Italy). The diluent 
was 0.9% sodium chloride intravenous infusion BP (batch 
number 05L22BS; Baxter Healthcare Ltd, Norfolk, England). 
The dose formulations of bupropion HCl and bupropion HBr 
were prepared in the same manner, with the 100 and 125 mg/
kg dose formulations prepared on study day –1 and that of the 
150 mg/kg dose on study day 0. The appropriate amount of 
bupropion HCl or bupropion HBr was weighed and dissolved 
in an appropriate amount of 0.9% NaCl and then shaken for 
5 min until it dissolved. Prepared test substances were stored 
at between 20–21 °C. On each study day, the single doses of 
test substances were administered by IP injection in a dose 
volume of 10 ml/kg and dose concentrations of 10, 12.5, and 
15 mg/ml for the 100, 125, and 150 mg/kg doses of bupropion 
HCl, and in a dose volume of 10 ml/kg and dose concentra-
tions of 11.6, 14.5, and 17.4 mg/ml for the 100, 125, and 
150 mg/kg equimolar doses of bupropion HBr. The actual dose 
administered was based on the body weight of each animal on 
study days 0 (100 and 125 mg/kg) and 1 (150 mg/kg).
Study procedure
All animals had a clinical examination on the day of arrival 
at the study facility to conﬁ  rm their suitability for the study 
and also, on study day –1. After the acclimatization period, on 
the day prior to the start of or the start day of study treatment 
(study day 0 for 100 and 125 mg/kg and day 1 for 150 mg/kg), 
all animals were weighed and the individual body weights 
were used for dose volume calculation. Treatment was then 
administered by IP injection and each group of animals was 
observed continuously for at least two hours post-treatment. 
Details of the number of mice with behavioral convulsions, 
the number of convulsions, the time of onset of the convul-
sions, the duration of each convulsion, and the intensity of 
each convulsion were noted. The intensity of each convulsion 
was graded using Charles River Laboratories, Inc.’s grading 
system of either mild: head and tail slightly extended and 
little jerking; or moderate: head and tail fully extended and 
some jerking; or severe: head and tail fully extended and 
strong jerking. Post hoc, the duration of each convulsion 
was classiﬁ  ed as short, medium or long. Short convulsions 
lasted 0–10 sec, medium convulsions lasted 11–30 sec, and 
long convulsions lasted 31 sec.
Assessment of behavioral convulsant activity
The primary outcome variable was the percentage (%) of 
mice that had behavioral convulsions. This was the number 
of animals with behavioral convulsions (mild, moderate, or 
severe) divided by the total number of animals in each group 
multiplied by 100. In addition, the CD50 or convulsive dose50, 
the convulsive dose required to induce convulsions in 50% of 
mice, were calculated for the dose-response curves for bupro-
pion HCl treatment and bupropion HBr treatment. The second-
ary outcome variables were the mean number of behavioral 
convulsions per mouse and the intensity of convulsions.
Behavioral impairment in mice
The acute behavioral toxicity of bupropion HBr was evaluated 
in comparison to that of equimolar doses of bupropion HCl 
following IP administration in the rotarod test in mice. The study 
was conducted at the University of Utah. All mice were housed, 
fed, and handled in a manner consistent with the recommen-
dations in the National Research Council Publication, “Guide 
for the Care and Use of Laboratory Animals.” No insecticides 
capable of altering hepatic drug metabolism enzymes were 
used in the animal facilities. All animals were euthanized in 
accordance with the Institute of Laboratory Resources poli-
cies on the humane care of laboratory animals following the 
completion of the test. Male albino CF1 mice (Charles River 
Laboratories, Inc., Wilmington, MA) weighing 25–30 g, were 
allowed free access to both food (Prolab RMH 3000; PMI 
Nutrition International, Inc., St. Louis, MO) and water except 
when they were removed from their cages for the experimental 
procedure. The test substances were administered IP in a volume 
of 0.01 ml/10 g body weight in 0.9% sodium chloride.
Determination of the median toxic dose
Minimal motor impairment was deﬁ  ned in mice by the stan-
dardized rotarod test ﬁ  rst described by Dunham and Miya.25 Neuropsychiatric Disease and Treatment 2009:5 195
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Inability of a mouse to maintain its equilibrium for a 1-min 
trial period in each of three trials when placed on a 1-inch 
knurled rod rotating at 6 rpm was used as an indication of 
such impairment. All quantitative in vivo toxicity studies 
were conducted at the previously determined time-to-peak 
pharmacodynamic effect (TPE). The effect of various doses 
of the HCl and HBr salt of bupropion on rotarod impairment 
was then quantiﬁ  ed in groups of eight mice until at least 
two points were established between the limits of 0% and 
100% rotarod toxicity. Doses of bupropion HCl adminis-
tered IP were 50, 60, 75, and 100 mg/kg. The corresponding 
equimolar doses of bupropion HBr administered IP (corrected 
for molecular weight) were 75, 85, 100, and 150 mg/kg.
Data management and statistical analysis
Mice EEG study
Data are presented as mean ± SD. The number and duration 
(in seconds) of EEG seizures in mice were compared between 
the two bupropion salts using unpaired Student’s t-test.
Histopathology study
The mean TUNEL counts of the combined counts from the 
two sides of the brain sections from bupropion HCl-treated 
mice were compared to the corresponding mean values 
obtained for the brain sections from the bupropion HBr-
treated mice and by brain region using the Student’s t-test.
Rat EEG study
The EEG signal was digitized at a sampling rate of 500 Hz/
recording-channel and the data was stored in raw data ﬁ  les. 
The analysis was performed off-line by visual inspection of 
the traces. The cortical and hippocampal traces were dis-
played individually for each rat on the computer screen at 
a time resolution of 10 sec/window and searched for patho-
logic activity. Representative samples of pathologic signals 
were saved in pdf-format ﬁ  les. The EEG irregularities found 
upon visual off-line inspection were reported descriptively. 
In addition, the EEG abnormalities were categorized as 
those occurring at baseline (one hour before IP injection of 
treatment) and those occurring during the two-hour post-
treatment period. Spike trains or spike-and-wave activity 
clearly exceeding baseline amplitudes and lasting at least 
one second were deﬁ  ned as seizure activity. Furthermore, 
the duration of any seizure activity was noted and classiﬁ  ed 
as either short seizure activity deﬁ  ned as seizure activity up 
to four seconds in duration, or long seizure activity deﬁ  ned 
as seizure activity between four and 60 seconds. The number 
of animals with EEG seizure activity and the mean duration 
of ﬁ  rst seizures were compared between the treatments using 
the Chi-square and unpaired Student’s t-tests.
Assessment of relative behavioral convulsant 
activity in mice
Data was summarized and presented in tables by treatment 
groups for the primary outcome variable, the percent (%) 
of convulsing mice, and the secondary outcome variables, 
the mean convulsions per mouse in each treatment group, 
and the intensity of convulsions. The CD50 values were 
calculated using the PROBIT procedure in SAS® version 
9.1 (SAS Institute., Cary, NC, USA). The 95% conﬁ  dence 
limits for CD50 were calculated according to the method of 
Litchﬁ  eld and Wilcoxon.26 The pooled data from the two 
studies (13 mice per dose per treatment; total = 39 animals per 
treatment) were used to calculate the CD50 for each treatment. 
The Cochran-Mantel-Haenszel test was used to detect if the 
pattern of the intensity (severity) of convulsions changes 
between the two treatments while adjusting for dose. p-values 
of 0.05 were considered statistically signiﬁ  cant.
Behavioral impairment in mice
The molar dose of each salt required to produce rotarod 
impairment in 50% of animals (ie, the TD50), the 95% con-
ﬁ  dence interval, the slope of the regression line, and the 
standard error of the mean (SEM) of the slope was calculated 
by a computer program based on the method described by 
Finney.27
All data are expressed as mean ± SD or mean ± SEM, 
and for all statistical analyses, a p-value of less than 0.05 was 
considered statistically signiﬁ  cant.
Results
Mice EEG study
Behavioral observations
The 150 mg/kg dose either salt of bupropion triggered 
strong seizure-like behavior within 5 min of injection. This 
was most pronounced during the early recording period 
(ﬁ  rst 15–20 min) but episodic events continued through the 
one hour of recording. In general, observations suggested 
behavioral signs of seizure-activity diminished ﬁ  rst in HCl-
treated mice.
Mice EEG ﬁ  ndings
Following the IP injection of 150 mg/kg of both salts in mice 
(n = 4 per salt), within the ﬁ  rst ﬁ  ve minutes after admin-
istration of salts brief (2–3 s) bursts of seizure-like EEG 
were detected in three of four HCl-treated and two of four Neuropsychiatric Disease and Treatment 2009:5 196
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HBr-treated mice that coincided with the onset of seizure-like 
behavior in the mice administered each of the salts. No other 
EEG seizure activity was detected in any of the four pairs of 
mice with either salt of bupropion following the brief bursts 
despite ongoing profound behavioral seizures/convulsions.
However, at the 125 mg/kg dose (n = 4 mice per salt), 
following injection of both salts, there was some signiﬁ  cant 
EEG seizure activity recorded in 3 pairs of mice with more 
seizure bursts in the bupropion HCl-administered animals. 
Both the mean number and duration of recorded EEG seizure 
activity were about 10 times more following the adminis-
tration of IP bupropion HCl 125 mg/kg compared to the 
equimolar dose of bupropion HBr, however, only the mean 
number of EEG seizures was statistically signiﬁ  cantly differ-
ent (bupropion HCl – 7.5 ± 5.3; bupropion HBr – 0.8 ± 1.0; 
p = 0.045) between the two salts (Table 1). No electrographic 
seizure activity was detected in either mouse with both salts 
in the fourth pair of mice tested at this dose.
No EEG seizure activity (Type IV seizure bursts) of 
any signiﬁ  cance were detected in any mouse with either 
bupropion salt following the administration of 100 mg/kg 
(n = 2 per salt), 115 mg/kg (n = 2 per salt), or 135 mg/kg 
(n = 2 per salt).
Mice histopathology ﬁ  ndings
Overall, there were either no TUNEL-positive cells in the 
brain sections of bupropion-treated mice or the mean counts 
were very low (less than 1) in the sections where they were 
present. The mean ± SD TUNEL counts in the bupropion 
HCl-treated mice brain were 0.3 ± 0.3, 0. 7 ± 0.3 and 0.0 for 
the hippocampal, caudate-putamen and substantia nigra sec-
tions, respectively. Similarly, the mean ± SD TUNEL counts 
in the bupropion HBr-treated mice brain were 0.3 ± 0.6, 
0.2 ± 0.3, and 0.0 for the hippocampal, caudate-putamen and 
substantia nigra sections, respectively. There were no sig-
niﬁ  cant differences between the mean TUNEL counts from 
the corresponding sections of the brains treated with either 
salt of bupropion. The few TUNEL-positive cells, where 
present, likely represent spontaneous/naturally occurring 
cell death. Essentially no cell death and hence, histopatho-
logical injury occurred in the brains of mice killed 24 hours 
after seizures induced by the administration of 125 mg/kg 
IP of bupropion HCl (Figure 1–E, K and Q) or bupropion 
HBr (Figure 1–H, N and T) compared to the control section 
from the CA3 area of the hippocampus of a mouse with 
kainic acid-induced seizures that showed TUNEL-positive 
cells (Figure 1–B).
Also, the Fluoro-Jade B-stained sections from all three 
regions of the brains of mice with bupropion HCl- (Figure 1–F, 
L and R) and bupropion HBr-induced (Figure 1–I, O and U) 
seizures did not reveal any Fluoro-Jade B-positive neurons 
compared to the control section from the hippocampus of 
a mouse with kainic acid-induced seizures that showed 
Fluoro-Jade B-positive neurons (Figure 1–C). The absence 
of Fluoro-Jade B-positive neurons in the sections indicates 
that there were no degenerating neurons and conﬁ  rms the 
ﬁ  ndings of TUNEL staining.
Immunostaining for neuron-specific antigen (NeuN 
immunostaining) of sections from the HCl/HBr treated mice 
conﬁ  rmed the normal appearance of morphology within 
neuronal populations in each brain region examined. No 
NeuN stained cells displayed signs of degeneration in mice 
treated at 125 mg/kg IP of bupropion HCl (Figure 1–D, 
J and P) or bupropion HBr (Figure 1–G, and S). These 
contrast with the ﬁ  ndings in the control section of the hip-
pocampus of a mouse with kainic acid-induced seizures 
where only a proportion of the cells were stained red (NeuN 
immunostaining), with the absence of red staining in the CA3 
pyramidal neuron subﬁ  eld of the ipsilateral hippocampus 
(Figure 1–A) indicating the absence of immunoreactivity 
probably from degradation of the NeuN antigen because the 
neurons were at the late stages of the degenerative process 
Table 1 Number and total duration of EEG seizures following intraperitoneal injection of bupropion hydrochloride 125 mg/kg and 
equimolar bupropion hydrbromide in mice
Mice pairs (n = 4) Number of EEG seizures Duration of EEG seizures (seconds)
Bupropion HCl Bupropion HBr Bupropion HCl Bupropion HBr
First 12 2 290 30
Second 8 1 130 25
Third 10 0 115 0
Fourth 0 0 0 0
Mean ± SD 7.5 ± 5.3 *0.8 ± 1.0 133.8 ± 119.3 13.8 ± 16.0
Notes: *p = 0.045 compared to corresponding mean for bupropion HCl by unpaired Student’s t-test.
Abbreviations: EEG, electroencephalogram; HCl, hydrochloride; HBr, hydrobromide; SD, standard deviation.Neuropsychiatric Disease and Treatment 2009:5 197
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Figure 1 Representative 40X lens images of NeuN (red), TUNEL (green) and Fluoro-Jade B (green) staining of hippocampal sections of control mice with kainic acid-induced 
(KA-seizure) seizures (A, B, C, respectively) and of hippocampal [CA3], substantia nigra [SubNigr] and caudate-putamen [C–P] sections of mice with bupropion HCl- (D, E, F, 
J, K, L, P, Q, R) and bupropion HBr-induced (G, H, I, M, N, O, S, T, U) seizures 24 hours following the administration of drug (Kainic acid or 125 mg/kg of bupropion salt). A–C: 
(A) shows NeuN immunostaining of some hippocampal area CA3 neurons particularly in the lower right side of the panel indicating the presence of neurons and the absence 
of NeuN staining in the upper left part of the panel indicating the loss of NeuN immunoreactivity probably from degradation of NeuN antigen from the degenerative process 
resulting from kainic acid-induced seizures; (B) a number of TUNEL-positive cells in the upper left part of the panel (arrows) indicating presence of cell death from kainic acid-
induced seizures; and (C) Fluoro-Jade B staining of degenerating neurons in hippocampal section stained bright yellow-green (arrows) against a dark background from kainic 
acid-induced seizures. D-U: NeuN immunostaining of large numbers of cells in sections from the hippocampus (D and G), substantia nigra (J and M) and caudate-putamen 
(P and S) of mice with bupropion HCl- and bupropion HBr-induced seizures, respectively, conﬁ  rming the presence of neurons; note absence of TUNEL-positive cells and hence, 
any cell death resulting from the administration of bupropion HCl or bupropion HBr in the hippocampus (E or H), substantia nigra (K or N), and caudate-putamen (Q or T); 
and similarly, note absence of Fluoro-Jade B-positive cells indicating the absence of degenerating neurons resulting from the administration of bupropion HCl or bupropion 
HBr in the hippocampus (F or I), substantia nigra (L or O), and caudate-putamen (R or U).
Notes: Bar in A, B, D, E, G, H, J, K, M, N, P, Q, S and T = 45 μm; and bar in C, F, I, L, O, R, and U = 500 μm.
Abbreviations: TUNEL, terminal deoxynucleotidyl dUTP nick end labeling; F-JB, Fluoro-Jade B; Bup-HCl, bupropion HCl; Bup-HBr, bupropion HBr.Neuropsychiatric Disease and Treatment 2009:5 198
Henshall et al
from seizure-induced injury. TUNEL and Fluoro-Jade B 
staining of the section revealed TUNEL-positive (Figure 1–B) 
and Fluoro-Jade B-positive (Figure 1–C) cells in that loca-
tion of the section conﬁ  rming the presence of dead and 
degenerating neurons, respectively.
EEG trace monitoring in the rat
Rat EEG ﬁ  ndings
Isolated and infrequent atypical EEG events of probably 
nonpathologic character were observed on various occasions 
at all doses. Some events were observed before and after 
substance administration and do not appear to be directly 
linked to or predispose to seizure activity. Also, in three rats, 
short seizure activity was observed in the hippocampus before 
bupropion HCl administration (baseline), which may be an 
indication that those rats were seizure prone. However, all 
three rats had been administered the test substance (30, 60, 
and 100 mg/kg respectively) the day before.
Following IP administration of test substance, there 
was no seizure activity observed in either the cortex or 
hippocampus in any rat administered bupropion HCl or 
bupropion HBr 10, 30, or 60 mg/kg. However, at 100 mg/kg, 
seizures were observed following both treatments with 
the seizures generally starting in the cortex, but of shorter 
duration in the hippocampus than in the cortex with both 
salt forms. Seizure onset delay was very short for both salt 
forms, and was approximately three minutes for the HCl 
salt and approximately two minutes for the HBr salt. In the 
bupropion HCl 100 mg/kg treatment group and following 
administration of treatment, all 10 rats had between one to 
four seizures recorded in both the cortex and hippocampus 
(Table 2; Figure 2A and B). In both the cortex and hippocam-
pus, of the 10 rats administered bupropion HCl 100 mg/kg, 
one rat had four seizures, four rats had two seizures each 
(except one that had one seizure only in the cortex), and 
the remaining ﬁ  ve had one seizure each. In contrast, at 
100 mg/kg in the bupropion HBr treatment group, only four 
rats had one seizure each in both the cortex and hippocampus 
(Table 2; Figure 3A and B). Between the two treatments at the 
100 mg/kg dose, there was a signiﬁ  cant difference (bupropion 
HCl = 10; bupropion HBr = 4; p  0.05) in the number of rats 
with seizure activity. All seizures observed following both 
treatments were long seizure activities (4–60 seconds), with 
no signiﬁ  cant difference in the mean duration of the initial 
seizure phase in the cortex and hippocampus between the 
two treatments (Table 2). However, the total duration of all 
occurrences of seizures were 424.6 and 361.2 seconds in the 
cortex and hippocampus, respectively, for bupropion HCl 
treatment, while it was 124.5 and 90.5 seconds in the cortex 
and hippocampus, respectively, for bupropion HBr treatment. 
This represents a 341% and 399% longer total duration of 
seizures in the cortex and hippocampus, respectively, in the 
bupropion HCl treatment group compared to the bupropion 
HBr group (Table 2).
Behavioral observations
Following the administration of bupropion HBr 10 mg/kg and 
60 mg/kg and prior to launching data acquisition, one rat had 
a short lasting facial clonus and a fatal whole body clonus, 
respectively, hence were not captured on the EEG. At the 
10 mg/kg dose, no abnormal behavior was observed following 
the administration of both treatments, while at the 30, 60, and 
100 mg/kg doses, all rats administered either the HCl salt but 
not the HBr salt (30 mg/kg) or both salts showed hyperactiv-
ity/stereotypical behavior. In addition, following bupropion 
HCl 100 mg/kg treatment, all 10 rats (100%) were observed 
to have convulsions expressed as facial clonus with or without 
forelimb clonus and rearing (Table 3). In contrast, following 
Table 2 Comparative effects of bupropion hydrochloride and bupropion hydrobromide on the EEG trace in rats: long seizure activity 
(4–60 seconds)
Treatment/number 
of animals
 
Number of 
animals with 
seizure activity
 
Duration of initial seizure 
(seconds)
Total duration of seizures† 
(seconds)
Cortex
(Mean ± SEM)
Hippocampus
(Mean ± SEM)
Cortex Hippocampus
Bupropion HCl 
100 mg/kg IP n = 10
10 33 ± 3 25 ± 4 424.6 361.2
Bupropion HBr* 
100 mg/kg IP n = 9**
4*** 31 ± 6 23 ± 2 124.5 90.5
Notes: †Total duration of seizures was the total duration of all seizures (initial and subsequent episodes) recorded in rats in each treatment group. *Dose of bupropion HBr 
is mg/kg of bupropion HCl molar equivalent (correction factor = 1.16). **One rat had a fatal whole body clonus after dosing with bupropion HBr 60 mg/kg IP prior to launching 
data acquisition, hence, it was not captured on the EEG. ***p  0.05 (Chi-square test) compared to the corresponding value for bupropion HCl.
Abbreviations: EEG, electroencephalogram; SEM, standard error of the mean; HCl, hydrochloride; IP, intraperitoneal injection; HBr, hydrobromide.Neuropsychiatric Disease and Treatment 2009:5 199
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bupropion HBr 100 mg/kg treatment, only ﬁ  ve rats (50%) 
were observed to have convulsions that were also expressed 
as facial clonus with or without forelimb clonus and rearing 
(except one rat that had a fatal whole body clonus). Between 
the two treatments at 100 mg/kg, the number of rats with 
moderate-to-severe convulsions (Racine23 Class III to V) 
were similar for both treatments. However, more rats in the 
bupropion HCl treatment group (70%) had mild convulsions 
compared to those in the bupropion HBr treatment group 
(20%) (Table 3). Furthermore, following both treatments, 
facial clonus was the most consistent behavioral correlate of 
long EEG seizure activity, both occurring simultaneously in 
all rats with seizures at the 100 mg/kg dose.
Assessment of relative convulsant 
activity in mice
Since the same doses of bupropion, study design, and strain 
of mice as in the dosage range-ﬁ  nding study24 were used in 
!
Figure 2 Five minutes of simultaneously recorded cortical (upper trace) and hippocampal (lower trace) EEG following the administration of bupropion hydrochloride 100 mg/kg 
intraperitoneally to a rat showing a seizure episode. A) The seizure lasted 35.2 seconds and 30.6 seconds in the cortex and hippocampus, respectively. The time and amplitude 
calibration bar is indicated between the traces to the left. The initial phase of the seizure activity is shown at higher time resolution. B) Behaviorally, hyperactivity/stereotypical 
behavior and facial clonus (Racine23 Class I) were observed simultaneously in the same rat. EEG = electroencephalogram.
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this deﬁ  nitive study, the results presented here are the pooled 
results of the two studies.
Percent (%) of convulsing mice
Administration of single doses of both treatments induced 
convulsions in mice in a dose-dependent manner with the 
125 and 150 mg/kg doses showing the largest effect with 
bupropion HCl and the 150 mg/kg dose with bupropion 
HBr (Figure 4). The percent of convulsing mice were 15%, 
100%, and 100% for bupropion HCl 100, 125 and 150 mg/kg, 
respectively, and 23%, 85%, and 100% for bupropion HBr 
100, 125, and 150 mg/kg, respectively. The CD50 or convulsive 
dose50 for bupropion HCl, the convulsive dose of bupropion 
HCl required to induce convulsions in 50% of mice was 
Figure 3 Five minutes of simultaneously recorded cortical (upper trace) and hippocampal (lower trace) electroencephalogram (EEG) following the administration of bupropion 
hydrobromide 100 mg/kg intraperitoneally to a rat showing a seizure episode. A) The seizure lasted 16.9 seconds and 16.7 seconds in the cortex and hippocampus, respectively. 
The time and amplitude calibration bar is indicated between the traces to the left. The initial phase of the seizure activity is shown at higher time resolution. B) Behaviorally, 
hyperactivity/stereotypical behavior, facial clonus and forelimb clonus (Racine23 Class III) were observed simultaneously in the same rat.
A
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103 mg/kg (conﬁ  dence intervals could not be estimated due 
to lack of data) while the CD50 for bupropion HBr was 110 
(CI: 100.3, 117.9) mg/kg. The CD50 values obtained for the 
two treatments were not statistically signiﬁ  cantly different.
Mean convulsions per mouse and intensity 
of convulsions
Single-dose bupropion HCl and bupropion HBr treatment 
induced a dose-dependent increase in both the total number of 
convulsions and the mean convulsions per mouse (Table 4). 
The mean convulsions per mouse varied from about 0 at the 
100 mg/kg dose to the highest rates at the 150 mg/kg dose for 
each treatment. Similarly, the intensity of convulsions (mild, 
moderate and severe) showed a dose-dependent increase from 
approximately 0 at the 100 mg/kg dose to the highest rates at 
the 150 mg/kg dose for each treatment (Table 4). However, 
bupropion HCl treatment appeared to have proportionately 
more severe convulsions at every dose level compared to 
bupropion HBr treatment. The Cochran–Mantel–Haenszel 
test performed to detect any general difference in the patterns 
of convulsion occurrence in terms of intensity (severity) 
between the two treatments while controlling for dose, 
showed that the association between treatment (HCl or HBr) 
and severity of convulsions, was statistically signiﬁ  cant 
(p  0.0001). This indicates that, given any dose level, 
there was statistical evidence that the two treatments had 
different patterns in terms of convulsion intensities. The latter 
results conﬁ  rm the earlier observation of a difference in the 
proportion of severe convulsions between the two treatments 
at the different dose levels.
Motor impairment in mice
In the preliminary determination of the TPE, no notable 
difference in the TPE between the two salts was noted, 
Table 3 Comparative behavioral effects of bupropion hydrochlo-
ride and bupropion hydrobromide in rats: severity of observed 
convulsions
Class 
(Racine 1972)*
Bupropion HCl 
100 mg/kg
IP (n = 10)
Bupropion HBr** 
100 mg/kg 
IP/(n = 10)
I 7 (70%) 2 (20%)
II – –
III – 1 (10%)
IV 2 (20%) 1 (10%)
V 1 (10%) 1 (10%)***
Notes: *Racine;23 **Dose of bupropion HBr is mg/kg of bupropion HCl molar 
equivalent (correction factor = 1.16); ***One rat had a fatal whole body clonus after 
dosing with bupropion HBr 60 mg/kg IP prior to launching data acquisition, hence, it 
was not captured on the EEG.
Abbreviations: EEG, electroencephalogram; HCl, hydrochloride; IP, intraperitoneal 
injection; HBr, hydrobromide.
Dose of Bupropion (mg/kg)
100 125 150
20
40
60
80
100
120 Bupropion HCl
Bupropion HBr
Figure 4 Dose-response curves of the percent (%) of convulsing mice following the intraperitoneal (IP) administration of bupropion HCl (closed circles) and bupropion HBr 
(open circles) in mice. The CD50 or Convulsing Dose50 values, the convulsant doses required to induce convulsions in 50% of mice were 103 (CI: could not be estimated due 
to lack of data) and 110 (CI: 100.3, 179.9) mg/kg for the dose-response curves for bupropion HCl and bupropion HBr, respectively. Doses of bupropion HCl administered IP 
were 100, 125, and 150 mg/kg. Bupropion HBr doses were molar equivalents of the bupropion HCl doses. Each data point is the % of convulsing mice in n = 13 mice.
Abbreviations: HCl, hydrochloride; HBr, hydrobromide.Neuropsychiatric Disease and Treatment 2009:5 202
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and peak intoxication as estimated by the rotarod test 
was observed at 15 minutes following IP administration. 
Therefore, the deﬁ  nitive rotarod test was performed at 
the TPE. Increasing IP doses of both the HBr and HCl 
salts of bupropion resulted in an impairment of rotarod 
performance. A time- (data not shown in Table 5) and 
dose-dependent impairment of rotarod performance was 
noted following the IP administration of both bupropion 
salts (Table 5). At the pre-determined TPE of 0.25 hour, 
the TD50 for the two salts were calculated to be 270.9 and 
286.8 μmol/kg (or 74.8 and 91.9 mg/kg, respectively) for 
bupropion HCl and bupropion HBr, respectively (Table 5). 
It is noteworthy that at the doses tested, no clinical seizures 
were observed in this test. Based on these results, no 
difference in rotarod performance was detected between 
the two salts of bupropion.
Discussion
Although bromides are no longer commonly used for 
the routine treatment of epilepsy in adults,12,28 they still 
have a role in the treatment of pediatric patients who are 
refractory to or who cannot tolerate other antiepileptic 
drugs.12 A new salt formulation of bupropion, bupropion 
HBr, has been developed for the treatment of patients with 
depression based on a number of factors. However, once 
developed it is important to determine whether or not the 
bromide component could potentially reduce the seizure risk 
associated with the use of bupropion in animals and humans. 
To test this hypothesis safety pharmacology studies need 
to be conducted to investigate its proconvulsant liability as 
well as any potential undesirable pharmacodynamic effects 
it may have on central nervous system (CNS) physiological 
functions.29 Therefore, the CNS safety pharmacology of 
bupropion HBr was assessed by comparing its effects 
to that of bupropion HCl on: (i) brain electrical seizure 
activity by quantiﬁ  ed EEG in conscious mice and rats; and 
(ii) on general behavioral effects including proconvulsant 
and motor coordination effects in conscious rats and mice. 
Equimolar but increasing doses of both salts of bupropion 
were administered IP to mice (100–150 mg/kg) and rats 
(10–100 mg/kg) in the EEG trace monitoring studies and 
to mice in the range 50–150 mg/kg to assess convulsive 
liability and motor impairment.
EEG seizures in mice
The results showed that signiﬁ  cant cortical EEG seizure 
activity was only detected at the 125 mg/kg dose, and 
bupropion HCl administration was associated with a 
ten-fold higher mean number of EEG seizures in mice 
that was statistically signiﬁ  cant compared to equimolar 
bupropion HBr even though no EEG seizure activity was 
detected in the fourth pair of mice dosed with either salt at 
this dose. Furthermore, the mean duration of seizures at the 
125 mg/kg dose showed a strong trend to overall increased 
Table 4 Total and mean convulsions per mouse by intensity and dose for the bupropion hydrochloride and bupropion hydrobromide 
treatments
Dose (mg/kg)* n = 13 per
dose per treatment**
Bupropion HCl Bupropion HBr
Total number
of convulsions
Mean convulsions
per mouse†
Total number
of convulsions
Mean convulsions
per mouse†
100
Severe 2 0.15 0 0.0
Moderate 1 0.08 1 0.08
Mild 0 0.0 9 0.69
125
Severe 128 9.85 79 6.08
Moderate 18 1.38 53 4.08
Mild 32 2.46 35 2.69
150
Severe 729 56.08 321 24.69
Moderate 113 8.69 156 12.00
Mild 81 6.23 129 9.92
Notes: *Dose levels are dose of bupropion HCl and doses of bupropion HBr are molar equivalent of bupropion HCl doses; **n = 13 mice per dose for bupropion HCl 
treatment, and for bupropion HBr treatment for pooled data from two studies; †Mean convulsions per mouse = the total number of convulsions divided by the number of 
mice in each dose group (n = 13 per group).
Abbreviations: HCl, hydrochloride; HBr, hydrobromide.Neuropsychiatric Disease and Treatment 2009:5 203
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seizure duration in the HCl group where the mean duration 
was ten-fold higher in mice administered bupropion HCl 
compared to equimolar bupropion HBr. The reason for the 
variable effect of the salts on the EEG at the 125 mg/kg dose 
observed in this study is not clear but it could be due to one 
or more number of factors, including simple and inherent in 
vivo biological variability, a CD-1 mouse-speciﬁ  c genotype 
effect, the use of female mice with the possible introduction 
of oestrous cycle events, and a higher than previous mouse 
study weight. The CD-1 mice used in the study were 25 g and 
higher in weight, which may be higher than was previously 
used for behavioral testing.
A surprising ﬁ  nding in this study was, at the 150 mg/
kg dose, very brief (2–3 seconds duration) cortical EEG 
activity was picked up that occurred equally following 
the administration of either salt of bupropion, with no 
further seizure activity detected thereafter despite the 
observed profound convulsive behavior. In addition, no 
EEG seizure activity was detected following dosing of 
mice with either salt of bupropion at the 100, 115, and 
135 mg/kg doses. This was surprising because in previous 
studies with bupropion HCl in mice, a dose-dependent 
increase in behavioral seizure activity was demonstrated in 
the dosage range 75 to 160 mg/kg.7,8,30 The reason for not 
detecting any EEG seizure activity even though profound 
behavioral convulsions were observed following the 
administration of 150 mg/kg of either salt, and at the 100, 
115, and 135 mg/kg doses is not known. However, it may 
reside with subcortical pathway activation and inhibition 
and hence, future studies employing simultaneous cortical 
and depth electrode recordings may yield the explanations 
for the lack of EEG recordings with the cortical electrodes 
used in this study.
Histopathology ﬁ  ndings in mice
An accumulated body of evidence shows that seizures induce 
a mixed pattern of cell death that includes features consistent 
with both apoptosis and necrosis,31–36 and more recently, that 
a signiﬁ  cant component of seizure-induced neuronal loss 
may be the result of programmed cell death pathways.37–41 
The histopathology study results showed the absence of 
TUNEL-positive cells and Fluoro-Jade B-positive neurons in 
the stained brain sections of mice indicating that no cell death 
or neuronal degeneration, respectively, occurred in mice 
killed 24 hours after seizures induced by the administration 
of 125 mg/kg IP of bupropion HCl or bupropion HBr. The 
latter complementary results taken together conﬁ  rmed that 
that neither the behavioral convulsions, nor the associated 
electrographic expression, induced by 125 mg/kg bupropion 
HCl (115–290 sec) and bupropion HBr (25–30 sec) in mice 
lead to cell death and/or neuronal degeneration as assessed 
by the highly sensitive in situ DNA fragmentation analysis 
(TUNEL)14,15 or the high afﬁ  nity ﬂ  uorescent marker (Fluoro-
Jade B),16,18 respectively. Furthermore, immunostaining 
for the neuron-speciﬁ  c antigen, NeuN,19 conﬁ  rmed that 
the morphology of neurons within hippocampus, striatum 
and substantia nigra were normal in mice treated with 
either bupropion salt. This ﬁ  nding of the absence of any 
histopathological injury following bupropion-induced 
seizures by either salt is signiﬁ  cant because more recently 
evidence has emerged that brief single and intermittent 
epileptic seizures can lead to neuronal death.34,39 Previously, 
Table 5 Dose-dependent motor impairment of bupropion hydrochloride and bupropion hydrobromide in the rotarod test in mice
Test 
compound
Time of test
(hour)
Dose
(mg/kg IP)
Number toxic/
Number tested*
TD50 (95% conﬁ  dence 
interval)
Bupropion HCl 0.25 50 0/8 74.8 mg/kg
60 1/8 (65.9–87.7)
75 5/8 or
100 7/8 270.9 μmol/kg
(238.6–317.4)
Bupropion HBr** 0.25 75 0/8 91.9 mg/kg
85 4/8 (83.5–111.1)
100 5/8 or
150 8/8 286.8 μmol/kg
       (260.3–346.3)
Notes: *Results are expressed as number of mice failing rotarod test over number of mice tested at each dose tested; **Doses of bupropion HBr are mg/kg of bupropion 
HCl molar equivalent.
Abbreviations: IP, intraperitoneal injection; TD50, toxic dose50 ie, the molar dose of each salt required to produce rotarod impairment in 50% of animals; HCl, hydrochloride; 
HBr, hydrobromide.Neuropsychiatric Disease and Treatment 2009:5 204
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epileptic brain injury had only been demonstrated after 
continuous and prolonged seizure activity or after a large 
number of severe intermittent seizures.31–33 Thus, while 
high dose bupropion may cause seizures, these animal data 
do not support their causing permanent neuronal loss in 
mouse brain.
EEG trace monitoring in rats
The results of this sub-study revealed that following the 
IP administration of both salts of bupropion at 100 mg/kg, 
bupropion HBr induced only single EEG seizure activity 
in the cortex and hippocampus, and in significantly 
(p  0.05) fewer rats (44%) compared to bupropion HCl 
that induced one to four convulsions per rat and in all the 
rats dosed (100%). The absence of EEG seizure activity 
at the 10, 30, and 60 mg/kg doses in this rat model is 
consistent with a previous report that bupropion HCl 
5–50 mg/kg IP did not produce any behavioral convulsions 
in mice7 and with reports of bupropion-induced behavioral 
convulsions in mice in the dosage range 75–160 mg/kg 
IP.7,8,30 Although there was no signiﬁ  cant difference in the 
mean duration of the ﬁ  rst seizure between the two treat-
ments in the cortex and hippocampus, the total duration of 
the multiple seizures following bupropion HCl treatment 
100 mg/kg were 341% and 399% longer in the cortex 
and hippocampus, respectively, compared to equimolar 
bupropion HBr treatment. In addition, all EEG seizure 
activity observed with both treatments were accompanied 
by simultaneous predominantly mild (facial clonus with 
or without forelimb clonus and rearing) behavioral 
convuslions, however, more rats in the bupropion HCl 
treatment group (70%) had mild convulsions (Racine23 
Class I – facial clonus) compared to the bupropion HBr 
treatment group (20%). Furthermore, facial clonus was 
the most consistent observed behavioral correlate of 
the long EEG seizure activity that was recorded follow-
ing treatment in all rats with seizures at the 100 mg/kg 
dose with both treatments. All these results indicate that 
bupropion HBr has a lower potency to induce convulsions 
compared to equimolar doses of bupropion HCl in normal 
conscious rats.
The short seizure activities observed in the hippocampus 
in three rats are most likely incidental ﬁ  ndings, since they 
occurred in an apparent random fashion. The reason(s) 
for the unexpected immediate reaction observed in one rat 
administered 10 mg/kg and another rat administered 60 mg/
kg bupropion HBr are not known but may indicate the need 
for further testing.
Behavioral proconvulsant activity in mice
The pooled data from the two studies in mice demonstrated 
that the administration of single doses of both treatments 
induced convulsions in mice in a dose-dependent manner. 
The CD50, the convulsive dose required to induce convul-
sions in 50% of mice for bupropion HCl was 103 mg/kg 
(conﬁ  dence intervals could not be estimated due to lack 
of data) while the corresponding value for bupropion HBr 
was 110 (CI: 100.3, 117.9) mg/kg. There was no signiﬁ  cant 
difference between the CD50 values obtained for the two 
treatments. The demonstration of dose-dependent convul-
sions in the dosage range 100–150 mg/kg in this study is 
consistent with the results of previous studies in mice.7,8,30 
In addition, the CD50 values of 103 and 110 mg/kg obtained 
in this study for bupropion HCl and bupropion HBr 
treatments, respectively, are similar to the values of 116.72 
(CI: 107.95, 126.20) and 119.7 (CI: 104.1, 137.6) mg/kg 
reported previously for IP bupropion HCl administration 
in mice.7,30
Also, single-dose bupropion HCl and bupropion HBr 
treatments induced a dose-dependent increase in the total 
number of convulsions, the mean convulsions per mouse, 
and in the intensity of convulsions (mild, moderate, and 
severe). The values observed for each parameter ranged 
from approximately 0 at the 100 mg/kg dose to the highest 
rates at the 150 mg/kg dose for each treatment. However, 
bupropion HCl treatment had proportionately more severe 
convulsions at every dose level compared to the bupropion 
HBr treatment. The Cochran–Mantel–Haenszel test while 
controlling for dose, showed that the association between 
treatment (bupropion HCl or bupropion HBr) and severity 
of convulsions was statistically signiﬁ  cant (p  0.0001), 
indicating that given any dose level, there was statistical 
evidence that the two treatments had different patterns in 
terms of convulsion intensities. These latter results support 
the earlier observation of a difference in the proportion 
of severe convulsions between the two treatments at the 
different dose levels.
Motor impairment in mice
A time- and dose-dependent impairment of rotarod 
performance in mice was noted following the IP administration 
of both bupropion salts in the dosage range studied. The TD50 
for the two salts were similar and were 270.9 and 286.8 μmol/
kg (or 74.8 and 91.9 mg/kg, respectively) for bupropion 
HCl and bupropion HBr, respectively. Although a time- and 
dose-dependent impairment of rotarod performance was 
observed with both bupropion salts, no difference in rotarod Neuropsychiatric Disease and Treatment 2009:5 205
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performance was detected between the two salts. Thus, 
the results of this study suggest that there is no difference 
between the effects of bupropion HCl and bupropion HBr 
to decrease neuromuscular coordination.
It is also important to note that the doses given to rodents 
were those that caused rotarod impairment. These are much 
higher than those given to patients (3–6 mg/kg/day). However, 
given the incidence of seizures in humans at these doses 
(0.1%–0.4%) it would be impractical to carry out animal 
studies at these dose ranges.
Conclusion
The results of these comparative safety pharmacology 
studies have demonstrated that following IP administration 
in mice, cortical EEG seizures were only detected at the 
125 mg/kg dose and bupropion HCl induced a ten-fold higher 
mean number of seizures that was statistically signiﬁ  cant 
compared to equimolar bupropion HBr. The EEG seizures 
induced by either salt of bupropion were not associated 
with any histopathological injury. In addition, in rats 
bupropion HBr 100 mg/kg induced only single cortical and 
hippocampal EEG seizure activity and in signiﬁ  cantly fewer 
animals (44%) compared to equimolar bupropion HCl that 
induced 1 to 4 convulsions per animal and in all rats dosed 
(100%). The total duration of the multiple seizures induced 
by bupropion HCl 100 mg/kg treatment were 341% and 
399% longer in the cortex and hippocampus, respectively, 
compared to that induced by equimolar bupropion HBr treat-
ment. All EEG seizure activity induced by both treatments 
were accompanied by simultaneous predominantly mild 
(facial clonus with or without forelimb clonus and rearing) 
behavioral seizures, however, more rats in the bupropion 
HCl treatment group (70%) had mild behavioral convulsions 
compared to the bupropion HBr treatment group (20%). 
Facial clonus was a consistent correlate of long EEG seizure 
activity. Both treatments induced behavioral convulsions in 
mice in a dose-dependent manner. There was no signiﬁ  cant 
difference in the CD50 values of the dose-response curves 
obtained for the two treatments. However, bupropion HCl 
consistently induced more severe convulsions at each 
dose level compared to bupropion HBr. Both treatments 
demonstrated a similar dose-dependent impairment of 
rotarod performance in mice. In summary, these results 
indicate that bupropion HBr appears to have a lower potency 
to induce EEG seizures in mice and rats, and less severe 
behavioral convulsions in mice compared to bupropion 
HCl. These interesting ﬁ  ndings merit further investigation 
in clinical safety studies.
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